These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 30452014)
1. Immunotherapy in Pediatric Oncology: An Overview of Therapy Types and Nursing Implications. Warren CB Clin J Oncol Nurs; 2018 Dec; 22(6):649-655. PubMed ID: 30452014 [TBL] [Abstract][Full Text] [Related]
2. Utilization of CAR T Cell Therapy in Pediatric Patients. Szenes V; Curran KJ Semin Oncol Nurs; 2019 Oct; 35(5):150929. PubMed ID: 31526551 [TBL] [Abstract][Full Text] [Related]
3. Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. Ceppi F; Beck-Popovic M; Bourquin JP; Renella R Eur J Pediatr; 2017 Sep; 176(9):1163-1172. PubMed ID: 28803259 [TBL] [Abstract][Full Text] [Related]
4. Combination Immunotherapy Approaches for Pancreatic Cancer Treatment. Cheng X; Zhao G; Zhao Y Can J Gastroenterol Hepatol; 2018; 2018():6240467. PubMed ID: 29707526 [TBL] [Abstract][Full Text] [Related]
5. Cancer Nanomedicine: Lessons for Immuno-Oncology. Sengupta S Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932 [TBL] [Abstract][Full Text] [Related]
6. Are peptide vaccines viable in combination with other cancer immunotherapies? Ohtake J; Sasada T Future Oncol; 2017 Aug; 13(18):1577-1580. PubMed ID: 28776424 [No Abstract] [Full Text] [Related]
7. A banner year for immunotherapy and targeted therapy. Carlisle JW; Ramalingam SS Nat Rev Clin Oncol; 2019 Feb; 16(2):79-80. PubMed ID: 30538305 [No Abstract] [Full Text] [Related]
8. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics. Mooradian MJ; Sullivan RJ Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423 [TBL] [Abstract][Full Text] [Related]
9. Advances in immunotherapy. Using the body's own immune system to fight cancer. Duke Med Health News; 2014 Aug; 20(8):6. PubMed ID: 25230429 [No Abstract] [Full Text] [Related]
10. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. Liu YH; Zang XY; Wang JC; Huang SS; Xu J; Zhang P Biomed Pharmacother; 2019 Dec; 120():109437. PubMed ID: 31590992 [TBL] [Abstract][Full Text] [Related]
12. The development of immunotherapy in older adults: New treatments, new toxicities? Helissey C; Vicier C; Champiat S J Geriatr Oncol; 2016 Sep; 7(5):325-33. PubMed ID: 27318796 [TBL] [Abstract][Full Text] [Related]
13. Are mimotope vaccines a good alternative to monoclonal antibodies? Pourjafar M; Samadi P; Khoshinani HM; Saidijam M Immunotherapy; 2019 Jun; 11(9):795-800. PubMed ID: 31094256 [TBL] [Abstract][Full Text] [Related]
14. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Yan Y; Kumar AB; Finnes H; Markovic SN; Park S; Dronca RS; Dong H Front Immunol; 2018; 9():1739. PubMed ID: 30100909 [TBL] [Abstract][Full Text] [Related]
15. Future directions for pediatric and young adult bone sarcoma. Finney J; Kent PM; Batus M Curr Probl Cancer; 2013; 37(4):225-35. PubMed ID: 24238588 [No Abstract] [Full Text] [Related]
17. Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Cheng JD; Rieger PT; von Mehren M; Adams GP; Weiner LM Semin Oncol Nurs; 2000 Nov; 16(4 Suppl 1):2-12. PubMed ID: 11151455 [TBL] [Abstract][Full Text] [Related]
18. [Role of Immunotherapy in Pediatric Oncology]. Bajčiová V Klin Onkol; 2015; 28 Suppl 4():4S38-43. PubMed ID: 26647887 [TBL] [Abstract][Full Text] [Related]
19. The application of the fibroblast activation protein α-targeted immunotherapy strategy. Jiang GM; Xu W; Du J; Zhang KS; Zhang QG; Wang XW; Liu ZG; Liu SQ; Xie WY; Liu HF; Liu JS; Wu BP Oncotarget; 2016 May; 7(22):33472-82. PubMed ID: 26985769 [TBL] [Abstract][Full Text] [Related]
20. Cancer Immunotherapy: The Dawn of Antibody Cocktails. Marrocco I; Romaniello D; Yarden Y Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]